Journal article

Pertuzumab: new hope for patients with HER2-positive breast cancer

M Capelan, L Pugliano, E De Azambuja, I Bozovic, KS Saini, C Sotiriou, S Loi, MJ Piccart-Gebhart

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2013

Abstract

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) overexpression is detected in approximately 15% to 20% of all breast cancers (BCs). A revolutionary change in the prognosis of this subgroup of patients has occurred since trastuzumab therapy was introduced into daily clinical practice. However, because trastuzumab resistance is common, new molecules with complementary and/or synergistic mechanisms of action have been developed. Pertuzumab is a new anti-HER2 humanized monoclonal antibody that prevents the formation of HER2 dimers. MATERIAL AND METHODS: A computer-based literature search was carried out using PubMed (keywords: breast neoplasm, dimerization, HER-2, pertuzumab); data r..

View full abstract